(VIANEWS) – At 15:51 EST on Monday, BergenBIO (BGBIO.OL) shares gained 9.79% to close at kr0.12, continuing gains from yesterday. Overall, Oslo Bors Benchmark Index_GI also registered gains, rising by 0.67%; its price was also up 0.65% with BergenBIO closing at 99.18% of its 52-week high of 13.03! It will be interesting to observe whether investors respond similarly in future trading sessions.
About BERGENBIO
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on discovering novel treatments for immune-evasive, drug-resistant, and metastatic cancers as well as respiratory illnesses. bemcentinib is a once-daily oral inhibitor of AXL receptor tyrosine kinase and currently being tested in Phase 1b/2a clinical trials for non-small cell lung cancer, acute myeloid leukemia and COVID-19; additional trials for glioblastoma, 2L lung cancer, melanoma pancreatic cancer and mesothelioma are ongoing. BerGenBio currently has two clinical trials underway – one for ovarian cancer using their anti-AXL function-blocking monoclonal antibody, Tilvestamab; and one for solid tumors using Mipasetamab uzoptirine. They have an agreement with Merck & Co and were established in Bergen Norway in 2007.
Yearly Analysis
Based on the provided information about BERGENBIO stock, here is an investment outlook:
* Yearly Top and Bottom Value: At present, BERGENBIO stock is trading at approximately kr0.12, significantly below its 52-week high of 13 and higher than its low of 0.08 respectively. This suggests that prices have fluctuated within its trading range over the past year as well as continue to do so moving forward.
* Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): BERGENBIO’s current EBITDA figure stands at -2.91, signalling it is currently operating at a loss and should cause concern among investors as this indicates the company isn’t producing enough profit to cover expenses.
Overall, investors should exercise extreme caution when considering investing in BERGENBIO stock as it currently trades lower than its 52-week high and has a negative EBITDA margin. Prior to making their final decision on an investment decision in this company’s shares, additional research may be beneficial on its financials, industry trends and growth prospects.
Technical Analysis
BERGENBIO stock has been on a decline, currently trading below both its 50-day and 200-day moving averages indicating bearish short and long term trends for this stock. Furthermore, volume trading activity appears to be higher than its average, suggesting greater trading activity within this stock.
However, despite BERGENBIO’s bearish trend, its volatility has been relatively low over the past week, month, and quarter, with average intraday variations being negative 1.19%, positive 0.89%, and positive 5.49% respectively. Its highest amplitude of average volatility occurred over these three timeframes with highest values reaching 4.62% last week, 6.18% last month, and 5.49 % last quarter.
Low volatility could indicate that investors are less concerned with BERGENBIO stock’s movements or liquidity issues; ultimately, though its stock has underperformed recently, its low volatility could indicate investors taking a more prudent approach towards it.
Equity Analysis
Bergenbio’s trailing twelve months EPS stands at kr-1.52, suggesting it is not currently profitable. Furthermore, their return on equity (ROE) for these twelve trailing months stands at negative 179.58% indicating their shareholders have not seen returns from their equity investment in them.
Investors should exercise extreme caution when investing in companies with negative return on equity (ROE). Before making any investment decisions, it’s vitally important to thoroughly evaluate a firm’s financial performance, management practices and growth prospects before making a final decision. Other considerations could include factors like competitive position, industry trends or overall market conditions as part of this evaluation process.
More news about BERGENBIO (BGBIO.OL).
